Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Waltz

Showing results (11-20 of 34) with videos related to

Pageof 4
Sort By:
The Lancet. Respiratory Medicine|January 29, 2019
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 studyJohn J McNamara, Susanna A McColley, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 22, 2008
Highlights of a workshop to discuss targeting inflammation in cystic fibrosisKatharine H Banner, Hugo De Jonge, Stuart Elborn, et al.
American Journal of Respiratory and Critical Care Medicine|October 27, 2023
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related EventsBonnie Ramsey, Christoph U Correll, David R DeMaso, et al.
Chest|February 11, 2004
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trialRichard B Moss, David Rodman, L Terry Spencer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
ERJ Open Research|June 21, 2019
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two <i>F508del</i> allelesJennifer L Taylor-Cousar, Marcus A Mall, Bonnie W Ramsey, et al.
Pediatric Pulmonology|December 2, 2004
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung diseaseRichard B Moss, Nicole Mayer-Hamblett, Jeffrey Wagener, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence|May 18, 2011
Machine learning for the New York City power gridCynthia Rudin, David Waltz, Roger N Anderson, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Pageof 4

Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
The Lancet. Respiratory Medicine|January 29, 2019
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 studyJohn J McNamara, Susanna A McColley, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 22, 2008
Highlights of a workshop to discuss targeting inflammation in cystic fibrosisKatharine H Banner, Hugo De Jonge, Stuart Elborn, et al.
American Journal of Respiratory and Critical Care Medicine|October 27, 2023
Elexacaftor/Tezacaftor/Ivacaftor Treatment and Depression-related EventsBonnie Ramsey, Christoph U Correll, David R DeMaso, et al.
Chest|February 11, 2004
Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trialRichard B Moss, David Rodman, L Terry Spencer, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|August 28, 2018
Lumacaftor/Ivacaftor reduces pulmonary exacerbations in patients irrespective of initial changes in FEV<sub>1</sub>Susanna A McColley, Michael W Konstan, Bonnie W Ramsey, et al.
ERJ Open Research|June 21, 2019
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two <i>F508del</i> allelesJennifer L Taylor-Cousar, Marcus A Mall, Bonnie W Ramsey, et al.
Pediatric Pulmonology|December 2, 2004
Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung diseaseRichard B Moss, Nicole Mayer-Hamblett, Jeffrey Wagener, et al.
IEEE Transactions on Pattern Analysis and Machine Intelligence|May 18, 2011
Machine learning for the New York City power gridCynthia Rudin, David Waltz, Roger N Anderson, et al.
American Journal of Respiratory and Critical Care Medicine|May 8, 2023
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children Aged ⩾6 Years with Cystic Fibrosis and at Least One <i>F508del</i> Allele: A Phase 3, Open-Label Clinical TrialClaire Wainwright, Susanna A McColley, Paul McNally, et al.
The Lancet. Respiratory Medicine|December 25, 2016
Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension studyMichael W Konstan, Edward F McKone, Richard B Moss, et al.
Pageof 4